BeyondSpring
  • About
    • Who We Are
    • Management Team
    • Scientific Advisors
    • Board of Directors
  • Pipeline & Research
    • Pipeline
    • Plinabulin
    • Protein Degradation
    • Other Pipeline
    • Posters & Publications
    • Collaborations
    • Expanded Access Policy
  • NEWS & MEDIA
  • Investors
    • Stock Overview
    • Events & Presentations
    • Financials & Filings
    • ESG
    • Corporate Governance
  • Careers
  • Contact Us
Select Page

International Association for the Study of Lung Cancer (IASLC) 20th World Conference on Lung Cancer (2019)

July 14, 2020

09.09.2019

International Association for the Study of Lung Cancer (IASLC) 20th World Conference on Lung Cancer (2019)

DUBLIN-3, a Phase (Ph) III Trial Comparing the Plinabulin (P)/Docetaxel(D) Combination with D Alone in Stage IIIb/IV NSCLC

RECENT NEWS ARTICLES

  • BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 Inhibitors
  • BeyondSpring and Professor K. Eisenmann of the University of Toledo College of Medicine Present Poster Highlighting Plinabulin’s Anti-cancer Efficacy in Primary and Recurrent Glioblastoma Patient Derived Invasive Neurosphere Models
  • BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price Requirement
  • SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” Symposium
  • SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors
  • BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
  • BeyondSpring and Leading Cancer Center to Present Poster at SITC’s 38th Annual Meeting
  • BeyondSpring to Participate in the R.W. Baird’s 2023 Global Healthcare Conference
  • SEED Therapeutics, BeyondSpring Subsidiary, Appoints Jackson Tai to Board of Directors
  • BeyondSpring and Leading Cancer Center Present Poster Highlighting Plinabulin’s Ability to Reduce Infectious Neutropenic Fever for Multiple Myeloma Patients Undergoing AHCT

RECENT MEDIA COVERAGE

  • TD Ameritrade Watch List
  • Managing Chemotherapy Toxicities for Improved Patient Outcomes
  • New Treatment Modalities: Protein Degraders And Molecular Glues Gain Traction
  • Seed Therapeutics blossoms in an $800M deal with Lilly
  • Seed Therapeutics Launches Protein Degradation Research Platform and Appoints Edward Dongheng Liu as Chief Financial Officer
  • BeyondSpring Forms Partnership Advisory Committee Comprised of Industry Veterans
  • JAMA Oncology Highlights Plinabulin’s Efficacy in Preventing Chemotherapy-Induced Neutropenia as a Monotherapy
  • Pegfilgrastim Plus Plinabulin Reduces Chemo-Induced Neutropenia in TAC-Treated Patients
  • Dr. Lan Huang Featured in Nature Titled “‘Innovation’ Nation”
  • Woman of the Week Podcast: Dr. Lan Huang, Co-founder, Chairman and Chief Executive Officer BeyondSpring
Investor Contact
IR@beyondspringpharma.com
Media Contact
PR@beyondspringpharma.com

BeyondSpring Inc.
+1 (646) 305-6387
general@beyondspringpharma.com

ABOUT

  • Who We Are
  • Management Team
  • Scientific Advisors
  • Board of Directors

PIPELINE & RESEARCH

  • Pipeline Overview
  • Plinabulin
  • Protein Degradation
  • Other Pipeline
  • Posters & Publications
  • Collaboration
  • Expanded Access Policy

INVESTORS

  • Stock Overview
  • Events & Presentations
  • Financials & Filings
  • Corporate Governance

CAREERS

  • Job Opportunities

NEWS & MEDIA

  • Press Releases
  • Media Coverage
BeyondSprings Inc LinkedIn   BeyondSprings Inc Twitter

BeyondSprings Inc LinkedIn      BeyondSprings Inc Twitter

©2021 BeyondSpring Inc. All rights reserved.   Privacy Notice   |   Terms of Use

We use cookies to ensure that we give you the best experience on our website. Please click “OK” to continue or read our Privacy & Cookie Policy.OkPrivacy policy